SG10202105499WA - Antibodies Against Fcrn And Use Thereof - Google Patents

Antibodies Against Fcrn And Use Thereof

Info

Publication number
SG10202105499WA
SG10202105499WA SG10202105499WA SG10202105499WA SG10202105499WA SG 10202105499W A SG10202105499W A SG 10202105499WA SG 10202105499W A SG10202105499W A SG 10202105499WA SG 10202105499W A SG10202105499W A SG 10202105499WA SG 10202105499W A SG10202105499W A SG 10202105499WA
Authority
SG
Singapore
Prior art keywords
antibodies against
against fcrn
fcrn
antibodies
Prior art date
Application number
SG10202105499WA
Other languages
English (en)
Inventor
Christopher Tenhoor
Arumugam Muruganandam
Robert Charles Ladner
Clive Wood
Alan J Bitonti
James Stattel
Kevin Mcdonnell
Liming Liu
Jennifer DUMONT
Aaron Sato
Original Assignee
Dyax Corp
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp, Bioverativ Therapeutics Inc filed Critical Dyax Corp
Publication of SG10202105499WA publication Critical patent/SG10202105499WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
SG10202105499WA 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof SG10202105499WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4815208P 2008-04-25 2008-04-25
US4850008P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
SG10202105499WA true SG10202105499WA (en) 2021-07-29

Family

ID=41203902

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202105499WA SG10202105499WA (en) 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof
SG10201804513WA SG10201804513WA (en) 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof
SG2014004063A SG196839A1 (en) 2008-04-25 2009-04-24 Antibodies against fcrn and use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201804513WA SG10201804513WA (en) 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof
SG2014004063A SG196839A1 (en) 2008-04-25 2009-04-24 Antibodies against fcrn and use thereof

Country Status (17)

Country Link
US (10) US8273351B2 (zh)
EP (3) EP2310415B8 (zh)
JP (5) JP6106854B2 (zh)
KR (4) KR102072896B1 (zh)
CN (3) CN104479017A (zh)
AU (1) AU2009238605B2 (zh)
BR (2) BRPI0910622A2 (zh)
CA (2) CA2722082C (zh)
ES (1) ES2650804T3 (zh)
HK (2) HK1160868A1 (zh)
IL (2) IL208846A (zh)
MX (1) MX2010011679A (zh)
NZ (1) NZ589451A (zh)
SG (3) SG10202105499WA (zh)
TW (3) TWI547287B (zh)
WO (1) WO2009131702A2 (zh)
ZA (1) ZA201007873B (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102072896B1 (ko) 2008-04-25 2020-02-03 다이액스 코포레이션 Ｆｃｒｎ에 대한 항체 및 이들의 용도
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
SG10201604493TA (en) * 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN113061993A (zh) * 2011-09-30 2021-07-02 中外制药株式会社 离子浓度依赖性结合分子文库
WO2013081143A1 (ja) 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
DK2818183T3 (da) * 2012-02-24 2020-06-15 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til at fremme forsvinden af antigen ved hjælp af Fc RIIB
CA2871468C (en) 2012-04-23 2021-09-21 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
ES2816700T3 (es) * 2012-12-21 2021-04-05 Biogen Ma Inc Anticuerpos anti-tau humanos
EP2970406B1 (en) 2013-03-15 2017-12-13 Affibody AB New polypeptides
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US20160075766A1 (en) * 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
MX2016002547A (es) * 2013-08-28 2016-06-17 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
BR112016014810B1 (pt) * 2013-12-24 2023-12-26 Argenx Bvba Antagonistas de fcrn e métodos de uso
US20170045528A1 (en) * 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
NZ737666A (en) 2014-04-30 2018-10-26 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
JP6568207B2 (ja) * 2014-05-19 2019-08-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒツジｂ細胞を用いて抗体を産生するための方法およびその使用
US10323066B2 (en) 2014-09-17 2019-06-18 Affibody Ab Neonatal Fc receptor binding dimer and methods of use
EP3240804A4 (en) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
AU2016211280B2 (en) * 2015-01-30 2021-11-25 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
ES2956662T3 (es) * 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
US10900965B2 (en) 2015-08-24 2021-01-26 University Of Cincinnati Methods and compositions for the detection of Fc receptor binding activity of antibodies
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR20230035439A (ko) * 2016-07-29 2023-03-13 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
EP3533870A4 (en) 2016-10-28 2020-04-08 NRL Pharma, Inc. LACTOFERRIN / ALBUMIN FUSION PROTEIN AND PRODUCTION METHOD THEREFOR
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
AU2018285577A1 (en) * 2017-06-15 2020-01-30 UCB Biopharma SRL Method for the treatment of immune thrombocytopenia
US11773168B2 (en) 2017-12-13 2023-10-03 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
BR112020025001A2 (pt) 2018-06-08 2021-03-23 Argenx Bvba composições e métodos para o tratamento da trombocitopenia imune
SG11202100419UA (en) * 2018-07-20 2021-02-25 Momenta Pharmaceuticals Inc Fcrn antibody compositions
AU2019361247A1 (en) 2018-10-16 2021-05-27 UCB Biopharma SRL Method for the treatment of Myasthenia Gravis
MX2021005048A (es) * 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
SG11202112010RA (en) 2019-06-07 2021-12-30 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
WO2021022249A1 (en) * 2019-08-01 2021-02-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2021160116A1 (zh) * 2020-02-10 2021-08-19 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
KR102507515B1 (ko) * 2020-08-26 2023-03-08 이화여자대학교 산학협력단 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
WO2023030501A1 (zh) * 2021-09-03 2023-03-09 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability
CN115645537A (zh) * 2022-10-25 2023-01-31 成都臻拓医药科技有限公司 FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途
CN116047054A (zh) * 2023-03-08 2023-05-02 江西赛基生物技术有限公司 用于检测血小板抗体的试剂盒及其制备方法和使用方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0317156B2 (en) 1987-11-09 1997-11-12 Becton, Dickinson and Company Method for analysis of hematopoietic cells in a sample
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE69731289D1 (de) * 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
KR100566859B1 (ko) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Ｒｎａ-단백질 융합물을 이용한 단백질의 선별
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
JP4578098B2 (ja) 2001-10-01 2010-11-10 ダイアックス、コープ 多重鎖真核ディスプレイベクターとその使用
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
JP2007501847A (ja) 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体
JP2008538919A (ja) * 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー ＦｃＲｎ抗体およびその使用
US20090092507A1 (en) * 2005-08-05 2009-04-09 Ramirez Jr Emilio A Fluid pump systems
EP1986690A4 (en) * 2006-01-25 2009-05-13 Univ New York State Res Found ANTIBODIES AGAINST FCRN FOR THE TREATMENT OF AUTO / ALLO IMMUNOIDES
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
MY163473A (en) 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
KR102072896B1 (ko) 2008-04-25 2020-02-03 다이액스 코포레이션 Ｆｃｒｎ에 대한 항체 및 이들의 용도
SG10201604493TA (en) * 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
MX2020005981A (es) * 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
BR112020025001A2 (pt) * 2018-06-08 2021-03-23 Argenx Bvba composições e métodos para o tratamento da trombocitopenia imune
WO2020236695A1 (en) * 2019-05-17 2020-11-26 Alexion Pharmaceuticals, Inc. Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases

Also Published As

Publication number Publication date
TWI453031B (zh) 2014-09-21
US8273351B2 (en) 2012-09-25
TWI547287B (zh) 2016-09-01
TW201630626A (zh) 2016-09-01
US20130078262A1 (en) 2013-03-28
TW201509430A (zh) 2015-03-16
BRPI0910622A2 (pt) 2020-03-10
ES2650804T3 (es) 2018-01-22
MX2010011679A (es) 2011-05-23
AU2009238605A1 (en) 2009-10-29
EP3670538A1 (en) 2020-06-24
CN108467431A (zh) 2018-08-31
EP2310415B8 (en) 2017-12-13
IL208846A (en) 2015-09-24
KR20160079912A (ko) 2016-07-06
CA3131470A1 (en) 2009-10-29
HK1207089A1 (zh) 2016-01-22
KR20190104432A (ko) 2019-09-09
KR101837329B1 (ko) 2018-03-09
TW201010720A (en) 2010-03-16
ZA201007873B (en) 2012-02-29
US20160222112A1 (en) 2016-08-04
US20140248287A1 (en) 2014-09-04
EP2310415B1 (en) 2017-10-11
IL208846A0 (en) 2011-01-31
JP2015143230A (ja) 2015-08-06
JP5989159B2 (ja) 2016-09-07
IL241091A0 (en) 2015-11-30
BR122021026834B1 (pt) 2022-11-08
US20090324614A1 (en) 2009-12-31
US9260520B2 (en) 2016-02-16
CN104479017A (zh) 2015-04-01
KR20110044729A (ko) 2011-04-29
CA2722082C (en) 2021-11-09
JP2011523351A (ja) 2011-08-11
US20160194397A1 (en) 2016-07-07
US20160222109A1 (en) 2016-08-04
US20130045218A1 (en) 2013-02-21
WO2009131702A3 (en) 2010-02-18
TWI593423B (zh) 2017-08-01
SG196839A1 (en) 2014-02-13
JP2019162105A (ja) 2019-09-26
US20160222108A1 (en) 2016-08-04
KR102072896B1 (ko) 2020-02-03
AU2009238605B2 (en) 2014-11-06
CA2722082A1 (en) 2009-10-29
US20160222111A1 (en) 2016-08-04
KR20170122286A (ko) 2017-11-03
SG10201804513WA (en) 2018-07-30
EP3348573B1 (en) 2020-04-22
WO2009131702A9 (en) 2010-09-23
CN102149729B (zh) 2014-08-20
JP6499132B2 (ja) 2019-04-10
NZ589451A (en) 2012-07-27
EP2310415A2 (en) 2011-04-20
IL241091B (en) 2018-02-28
CN102149729A (zh) 2011-08-10
JP2022115960A (ja) 2022-08-09
EP3348573A1 (en) 2018-07-18
KR101634719B1 (ko) 2016-06-29
WO2009131702A2 (en) 2009-10-29
US20160222110A1 (en) 2016-08-04
JP2017029149A (ja) 2017-02-09
US8815246B2 (en) 2014-08-26
HK1160868A1 (zh) 2012-08-17
JP6106854B2 (ja) 2017-04-05

Similar Documents

Publication Publication Date Title
IL241091B (en) Antibodies to fcrn and their use
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
EP2236604A4 (en) ANTI-NR10 ANTIBODIES AND USE THEREOF
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
PL2099826T3 (pl) Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
HK1209130A1 (zh) 免疫球蛋白變體及其用途
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
HK1156326A1 (en) Anti-hepcidin-25 selective antibodies and uses thereof
IL207129A0 (en) Ron antibodies and uses thereof
IL236237A (en) Tmem154 antibodies and their segments and uses
IL212040A0 (en) Hepatitis c antibodies and uses thereof
HK1203206A1 (zh) 抗體及其應用
GB0807018D0 (en) Antibodies and treatment
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
EP2322610A4 (en) ANTI-CLCP1 HUMAN ANTIBODIES AND USE THEREOF
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
GB0812277D0 (en) Antibody and uses thereof
ZA200905136B (en) Anti-robo4 antibodies and uses therefor
HU0800405D0 (en) Ewnvironment-friendly biocidis and use thereof